TORONTO- Moderna Canada announces the appointment of Roger-Ketcha Ngassam as the Manufacturing Site Head for its mRNA vaccine manufacturing facility. A seasoned leader with local roots and extensive international experience, Roger will oversee the planning, construction, and execution at Moderna’s Good Manufacturing Practice (GMP) site, currently under construction in Laval, Quebec. He will also lead the local team recruitment as …
LONDON – In January 2023, the US FDA granted mRNA-1345 Breakthrough Therapy Designation for the prevention of RSV-LRTD in adults aged 60 years or older, and mRNA-1345 was previously granted Fast Track designation by the U.S. FDA in August 2021.“We’ve seen the impact that respiratory viruses like RSV can have on the health and wellbeing of Canadians. As we approach …
Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines Moderna is prepared to deliver updated COVID-19 vaccines in time for the fall 2023 vaccination season TORONTO – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada …
TORONTO – Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2. This follows Moderna’s submission to the U.S. Food and Drug Administration for …
